Ibtihal Siddiq Abdelgadir 1,2 , Morris A Gordon 3 , Anthony K Akobeng 1,2 Show Affiliations »
Abstract
IMPORTANCE: Children with neurodevelopmental disorders have a higher prevalence of sleep disturbances. Currently there is variation in the use of melatonin; hence, an up-to-date systematic review is indicated to summarise the current available evidence. OBJECTIVE: To determine the efficacy and safety of melatonin as therapy for sleep problems in children with neurodevelopmental disorders. DATA SOURCES AND STUDY SELECTIONS: PubMed, Embase, the Cumulative Index to Nursing and Allied Health Literature and the Cochrane Central Register of Controlled Trials were searched from inception up to January 2018. Two reviewers performed data assessment and extraction. We assessed randomised controlled trials that compared melatonin with placebo or other intervention for the management of sleep disorders in children (<18 years) with neurodevelopmental disorders. DATA EXTRACTION AND SYNTHESIS: We identified 3262 citations and included 13 studies in this meta-analysis. MAIN OUTCOMES: Main outcomes included total sleep time, sleep onset latency, frequency of nocturnal awakenings and adverse events. RESULTS: Thirteen randomised controlled trials (n=682) met the inclusion criteria. A meta-analysis of nine studies (n=541) showed that melatonin significantly improved total sleep time compared with placebo (mean difference (MD)=48.26 min, 95% CI 36.78 to 59.73, I2=31%). In 11 studies (n=581), sleep onset latency improved significantly with melatonin use (MD=-28.97, 95% CI -39.78 to -18.17). No difference was noted in the frequency of nocturnal awakenings (MD=-0.49, 95% CI -1.71 to 0.73). No medication-related serious adverse event was reported. CONCLUSION: Melatonin appeared safe and effective in improving sleep in the studied children. The overall quality of the evidence is limited due to heterogeneity and inconsistency. Further research is needed. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
IMPORTANCE: Children with neurodevelopmental disorders have a higher prevalence of sleep disturbances . Currently there is variation in the use of melatonin ; hence, an up-to-date systematic review is indicated to summarise the current available evidence. OBJECTIVE: To determine the efficacy and safety of melatonin as therapy for sleep problems in children with neurodevelopmental disorders . DATA SOURCES AND STUDY SELECTIONS: PubMed, Embase, the Cumulative Index to Nursing and Allied Health Literature and the Cochrane Central Register of Controlled Trials were searched from inception up to January 2018. Two reviewers performed data assessment and extraction. We assessed randomised controlled trials that compared melatonin with placebo or other intervention for the management of sleep disorders in children (<18 years) with neurodevelopmental disorders . DATA EXTRACTION AND SYNTHESIS: We identified 3262 citations and included 13 studies in this meta-analysis. MAIN OUTCOMES: Main outcomes included total sleep time, sleep onset latency, frequency of nocturnal awakenings and adverse events. RESULTS: Thirteen randomised controlled trials (n=682) met the inclusion criteria. A meta-analysis of nine studies (n=541) showed that melatonin significantly improved total sleep time compared with placebo (mean difference (MD)=48.26 min, 95% CI 36.78 to 59.73, I2=31%). In 11 studies (n=581), sleep onset latency improved significantly with melatonin use (MD=-28.97, 95% CI -39.78 to -18.17). No difference was noted in the frequency of nocturnal awakenings (MD=-0.49, 95% CI -1.71 to 0.73). No medication-related serious adverse event was reported. CONCLUSION: Melatonin appeared safe and effective in improving sleep in the studied children . The overall quality of the evidence is limited due to heterogeneity and inconsistency. Further research is needed. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Entities: Chemical
Disease
Species
Keywords:
neurodevelopment; paediatric practice; sleep; therapeutics
Mesh： See more »
Substances： See more »
Year: 2018
PMID： 29720494 DOI： 10.1136/archdischild-2017-314181
Source DB: PubMed Journal: Arch Dis Child ISSN： 0003-9888 Impact factor: 3.791